Compare Natera Inc. Common Stock (NTRA) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Exxon Mobil Corporation — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Exxon Mobil Corporation trades at $177.81 (market cap $727.85B). The key difference: Exxon Mobil Corporation is far larger — about 12.8× Natera Inc. Common Stock's market cap, and Exxon Mobil Corporation pays a 2.33% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Exxon Mobil Corporation for 100 Days on average.
| NTRA | XOM | |
|---|---|---|
Market Cap | $57.03B | $727.85B |
Volume | 1,131,157 | 10,493,203 |
Sector | Health | Energy |
52-Week High | $425.64 | $177.06 |
52-Week Low | $179.42 | $110.64 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $56.18B | $759.63B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ExxonMobil (XOM) trades at $174.13, up 1.15% with a bullish technical signal from moving averages. The company maintains strong profitability with 9.07% net margin and 12.55% ROE, though revenue declined to $323.91B in 2025. Recent developments include negotiations to return to Venezuela's oil fields and expansion in Guyana and Permian Basin assets targeting 5.5 MMBoe/d production by 2030.
XOM presents a mixed outlook with analyst consensus at Hold (56.37%) and $166.67 price target below current levels. Upside potential exists from strategic expansions and LNG market growth, but risks include declining revenue trends, geopolitical exposure in Venezuela, and refinery operational challenges. The stock trades near resistance at $174 with RSI indicating overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
